Be the most informed person in the room with Newsy's free e-newsletter

View our privacy policy:
Trump's Conflicts of Interest
Featured Series: Trump's Conflicts of Interest
Donald Trump's international web of businesses creates unprecedented potential for conflicts of interest and corruption. And some picks for his administration might have to face their own...

EpiPen Maker May Have Cheated Government Out Of Millions Of Dollars

Mylan has been accused of classifying EpiPens as a generic drug to pay a smaller rebate to Medicaid.

Mylan's found itself in another EpiPen scandal; only this time, the company may have overcharged the U.S. government.

On Wednesday, two members of Congress accused Mylan of misclassifying its emergency allergy medication as a generic drug so it could pay less in rebates to Medicaid. 

SEE MORE: Lawmaker Says Mylan's Lobbying Opened The Door For EpiPen Scrutiny

Instead of paying a 23 percent rebate for a brand-name drug, Mylan has been paying a 13 percent rebate. That amounts to millions of dollars less to the government and taxpayers who need the drug.

At the same time, Mylan raised the price of a single pen to roughly $300 this year. 

Mylan may have a harder time arguing EpiPens fall under the generic drug category, since during the height of its previous price scandal, the company said it would start selling a generic version of EpiPens for half-price. 

Featured Stories
Activists opposed to the Dakota Access Pipeline march in Washington, D.C.

Trump Signs Actions To Push Along Keystone XL, Dakota Access Pipelines

Mike Pompeo and Rex Tillerson

Pompeo Confirmed For CIA Head, Rex Tillerson Approved By Senate Panel

Donald Trump

Clean Energy Or Fossil Fuels? The President And The Country Disagree

Want to see more stories like this?
Like Newsy on Facebook for More Business Coverage